Organogenesis Holdings Inc. (ORGO) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Organogenesis Holdings Inc. (ORGO) Bundle
Looking to assess the intrinsic value of Organogenesis Holdings Inc.? Our (ORGO) DCF Calculator merges real-world data with extensive customization features, enabling you to refine your forecasts and enhance your investment choices.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 261.0 | 338.3 | 468.1 | 450.9 | 433.1 | 498.5 | 573.8 | 660.4 | 760.1 | 874.8 |
| Revenue Growth, % | 0 | 29.63 | 38.36 | -3.67 | -3.94 | 15.09 | 15.09 | 15.09 | 15.09 | 15.09 |
| EBITDA | -21.9 | 37.2 | 87.0 | 40.3 | 36.0 | 38.4 | 44.1 | 50.8 | 58.5 | 67.3 |
| EBITDA, % | -8.38 | 11 | 18.59 | 8.94 | 8.32 | 7.69 | 7.69 | 7.69 | 7.69 | 7.69 |
| Depreciation | 9.4 | 8.2 | 16.7 | 18.0 | 23.4 | 19.0 | 21.8 | 25.1 | 28.9 | 33.3 |
| Depreciation, % | 3.61 | 2.42 | 3.56 | 4 | 5.41 | 3.8 | 3.8 | 3.8 | 3.8 | 3.8 |
| EBIT | -31.3 | 29.0 | 70.3 | 22.3 | 12.6 | 19.4 | 22.3 | 25.7 | 29.6 | 34.0 |
| EBIT, % | -12 | 8.59 | 15.02 | 4.94 | 2.9 | 3.89 | 3.89 | 3.89 | 3.89 | 3.89 |
| Total Cash | 60.2 | 84.4 | 113.9 | 102.5 | 104.3 | 118.8 | 136.7 | 157.4 | 181.1 | 208.5 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 39.4 | 56.8 | 82.5 | 89.5 | 82.0 | 88.0 | 101.3 | 116.6 | 134.2 | 154.4 |
| Account Receivables, % | 15.08 | 16.79 | 17.62 | 19.84 | 18.93 | 17.65 | 17.65 | 17.65 | 17.65 | 17.65 |
| Inventories | 22.9 | 27.8 | 25.0 | 24.8 | 28.3 | 34.3 | 39.4 | 45.4 | 52.2 | 60.1 |
| Inventories, % | 8.78 | 8.22 | 5.35 | 5.5 | 6.52 | 6.87 | 6.87 | 6.87 | 6.87 | 6.87 |
| Accounts Payable | 28.4 | 23.4 | 29.3 | 32.3 | 30.7 | 38.2 | 44.0 | 50.6 | 58.3 | 67.0 |
| Accounts Payable, % | 10.88 | 6.91 | 6.27 | 7.17 | 7.09 | 7.66 | 7.66 | 7.66 | 7.66 | 7.66 |
| Capital Expenditure | -6.2 | -21.1 | -31.2 | -33.9 | -24.4 | -28.4 | -32.6 | -37.6 | -43.3 | -49.8 |
| Capital Expenditure, % | -2.39 | -6.25 | -6.67 | -7.52 | -5.62 | -5.69 | -5.69 | -5.69 | -5.69 | -5.69 |
| Tax Rate, % | 52.42 | 52.42 | 52.42 | 52.42 | 52.42 | 52.42 | 52.42 | 52.42 | 52.42 | 52.42 |
| EBITAT | -31.4 | 27.1 | 103.9 | 17.1 | 6.0 | 16.2 | 18.6 | 21.5 | 24.7 | 28.4 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -62.1 | -13.2 | 72.4 | -2.6 | 7.4 | 2.3 | -4.9 | -5.6 | -6.5 | -7.4 |
| WACC, % | 10.33 | 10.27 | 10.33 | 10.1 | 9.82 | 10.17 | 10.17 | 10.17 | 10.17 | 10.17 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -15.1 | |||||||||
| Long Term Growth Rate, % | 3.50 | |||||||||
| Free cash flow (T + 1) | -8 | |||||||||
| Terminal Value | -115 | |||||||||
| Present Terminal Value | -71 | |||||||||
| Enterprise Value | -86 | |||||||||
| Net Debt | 16 | |||||||||
| Equity Value | -102 | |||||||||
| Diluted Shares Outstanding, MM | 133 | |||||||||
| Equity Value Per Share | -0.77 |
What You Will Get
- Real Organogenesis Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Organogenesis Holdings Inc.'s (ORGO) fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.
Key Features
- Customizable Forecast Inputs: Adjust essential metrics such as revenue growth, EBITDA %, and capital expenditures.
- Instant DCF Valuation: Automatically computes intrinsic value, NPV, and additional outputs in real-time.
- High-Precision Accuracy: Leverages Organogenesis Holdings Inc.'s (ORGO) actual financial data for credible valuation results.
- Simplified Scenario Analysis: Effortlessly evaluate various assumptions and assess results side by side.
- Efficiency Booster: Remove the necessity of constructing intricate valuation models from the ground up.
How It Works
- Download the Template: Gain immediate access to the Excel-based ORGO DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
- Instant Calculations: The model automatically recalculates Organogenesis Holdings Inc.'s intrinsic value.
- Test Scenarios: Experiment with different assumptions to assess potential valuation shifts.
- Analyze and Decide: Utilize the results to inform your investment or financial decisions.
Why Choose This Calculator for Organogenesis Holdings Inc. (ORGO)?
- Accurate Data: Utilize real Organogenesis financials for dependable valuation outcomes.
- Customizable: Modify essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-configured calculations save you the effort of starting from the ground up.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants in the biotech sector.
- User-Friendly: Designed with an intuitive interface and clear instructions for users of all experience levels.
Who Should Use Organogenesis Holdings Inc. (ORGO)?
- Healthcare Investors: Make informed investment choices with a comprehensive analysis of the regenerative medicine market.
- Market Analysts: Streamline your research with ready-to-use financial models tailored for the biotech sector.
- Consultants: Easily modify reports and presentations to showcase insights on Organogenesis Holdings Inc. (ORGO) for your clients.
- Biotech Enthusiasts: Enhance your knowledge of regenerative medicine and its valuation through practical examples.
- Educators and Students: Utilize it as a valuable resource for learning about healthcare finance and biotechnology in academic settings.
What the Template Contains
- Comprehensive DCF Model: Editable template featuring detailed valuation calculations for Organogenesis Holdings Inc. (ORGO).
- Real-World Data: Historical and projected financials for Organogenesis preloaded for in-depth analysis.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights into Organogenesis Holdings Inc. (ORGO).
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics.
- Dashboard with Visual Outputs: Charts and tables designed for clear, actionable insights.